Taxifolin is a novel therapeutic agent for Alzheimer’s disease and cerebral amyloid angiopathy

Impaired amyloid‐β clearance from brain along intramural periarterial drainage (IPAD) is key in the pathogenesis of Alzheimer’s disease (AD). Facilitating IPAD would delay or prevent cerebral amyloid angiopathy (CAA). Taxifolin, a flavonol with strong anti‐oxidative and anti‐glycation activities, has been reported to disassemble amyloid‐β. Here, we test the hypothesis that taxifolin has therapeutic potential in reducing AD and CAA.